John Ormiston

2.2k citations

32 papers · 1.6k indexed · h-index 21

Impact in

Cardiology and Cardiovascular Medicine top 2%
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Valve Diseases and Treatments
- Acute Myocardial Infarction Research
Surgery top 2%
- Coronary Interventions and Diagnostics
- Peripheral Artery Disease Management

Papers in ⓘ

Cardiology and Cardiovascular Medicine 22
- Antiplatelet Therapy and Cardiovascular Diseases 12
- Cardiac Valve Diseases and Treatments 10
- Acute Myocardial Infarction Research 3
- Atrial Fibrillation Management and Outcomes 2
Surgery 27
- Coronary Interventions and Diagnostics 24
- Lipoproteins and Cardiovascular Health 3

Co-authors: Dariusz Dudek (4 shared papers)Mark Webster (11 shared papers)Antonio Colombo (4 shared papers)Leif Thuesen (3 shared papers)Eduardo Sousa (2 shared papers)Eulogio García (1 shared paper)Wim van der Giessen (1 shared paper)Silvio Klugmann (1 shared paper)
Journals: EuroIntervention (13 papers)Journal of the American College of Cardiology (6 papers)JACC: Cardiovascular Interventions (4 papers)American Heart Journal (1 paper)The Lancet (1 paper)
Partner nations: New Zealand Netherlands Australia

In The Last Decade

John Ormiston

32 papers receiving 1.5k citations

Peers

Countries citing papers authored by John Ormiston

Since Specialization

Citations

This map shows the geographic impact of John Ormiston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Ormiston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Ormiston more than expected).

Fields of papers citing papers by John Ormiston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Ormiston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Ormiston. The network helps show where John Ormiston may publish in the future.

Co-authors

The 25 scholars most cited alongside John Ormiston, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Ormiston Line = papers co-authored together John Ormiston links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) The Lancet ·Patrick W Serruys, Ben van Hout, Hans Bonnier, Victor Legrand, Eulogio García, Carlos Macaya, Eduardo Sousa, Wim van der Giessen, Antonio Colombo, Ricardo Seabra‐Gomes, Ferdinand Kiemeneij, Peter Ruygrok, John Ormiston, Håkan Emanuelsson, Jean Fajadet, Michael Haude, Silvio Klugmann, Marie‐Angèle Morel	1998	499
2	A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis Journal of the American College of Cardiology ·Patrick W. Serruys, John Ormiston, Robert‐Jan van Geuns, Bernard De Bruyne, Dariusz Dudek, Evald Høj Christiansen, Bernard Chevalier, Pieter Smits, Dougal McClean, Jacques Koolen, Stephan Windecker, Robert Whitbourn, Ian T. Meredith, Luc Wasungu, Divine Ediebah, Susan Veldhof, Yoshinobu Onuma	2016	119
3	First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. PubMed ·Ian T. Meredith, John Ormiston, Robert Whitbourn, I Kay, David W.M. Muller, Raoul Bonan, Jeffrey J. Popma, Donald E. Cutlip, Peter J. Fitzgerald, Ross Prpic, Richard E. Kuntz	2005	108
4	Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial EuroIntervention ·Dariusz Dudek, Yoshinobu Onuma, John Ormiston, Leif Thuesen, Karine Miquel‐Hébert, Patrick W. Serruys	2012	101
5	Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial EuroIntervention ·Yosinobu Onuma, Patrick W. Serruys, John Ormiston, Evelyn Regar, Mark Webster, Leif Thuesen, Dariusz Dudek, Susan Veldhof, Richard Rapoza	2010	95
6	The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response JACC: Cardiovascular Interventions ·Patrick Gladding, Mark Webster, Irene Zeng, Helen Farrell, Jim Stewart, P. Ruygrok, John Ormiston, Seif El‐Jack, Guy Armstrong, Patrick Kay, Douglas Scott, Arzu Gunes, Marja‐Liisa Dahl	2008	93
7	Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. PubMed ·Jean Fajadet, William Wijns, Laarman Gj, Kuck Kh, John Ormiston, Thomas Münzel, Popma Jj, Fitzgerald Pj, R Bonan, Kuntz Re	2007	67
8	9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation Lesions Journal of the American College of Cardiology ·Stefan Verheye, Pierfrancesco Agostoni, Christophe Dubois, Joseph Dens, John Ormiston, Stephen G. Worthley, Brett Trauthen, Takao Hasegawa, Bon‐Kwon Koo, Peter J. Fitzgerald, Roxana Mehran, Alexandra J. Lansky	2009	63
9	The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel JACC: Cardiovascular Interventions ·Patrick Gladding, Mark Webster, Irene Zeng, Helen Farrell, Jim Stewart, P. Ruygrok, John Ormiston, Seif El‐Jack, Guy Armstrong, Patrick Kay, Douglas Scott, Arzu Gunes, Marja‐Liisa Dahl	2008	45
10	Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study EuroIntervention ·Jean Fajadet, William Wijns, GertJan Laarman, Karl‐Heinz Kück, John Ormiston, Stephan Baldus, Karl Eugen Hauptmann, Maarten J. Suttorp, J Drzewiecki, Michael Pieper, Heinz‐Peter Schultheiss, Laura Mauri	2010	38
11	A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study EuroIntervention ·Patrick W. Serruys, Scot Garg, Alexandre Abizaid, John Ormiston, Stephan Windecker, Stefan Verheye, Christophe Dubois, Jim Stewart, Karl E. Hauptmann, Joachim Schöfer, Karl Stangl, Bernhard Witzenbichler, Marcus Wiemer, Emanuele Barbato, Ton de Vries, Anne-Marie den Drijver, Hiromasa Otake, Lynn Meredith, Sara Toyloy, Peter J. Fitzgerald	2010	38
12	Antiplatelet drug nonresponsiveness American Heart Journal ·Patrick Gladding, Mark Webster, John Ormiston, Sarah Olsen, Harvey D. White	2008	37
13	Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer JACC: Cardiovascular Interventions ·Patrick Gladding, Harvey D. White, Jamie Voss, John Ormiston, Jim Stewart, P. Ruygrok, Badi Bvaldivia, Ruth Baak, Catherine A. White, Mark Webster	2009	35
14	Revascularization for Unprotected Left Main Disease Journal of the American College of Cardiology ·David E. Kandzari, Antonio Colombo, Seung‐Jung Park, Carl L. Tommaso, Stephen G. Ellis, Luis A. Guzmán, Paul S. Teirstein, Corrado Tamburino, John Ormiston, Gregg W. Stone, George Dangas, Jeffrey J. Popma, Theodore A. Bass	2009	32
15	Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial EuroIntervention ·Ian T. Meredith, Stephen G. Worthley, Robert Whitbourn, D. Walters, Dougal McClean, John Ormiston, M. Horrigan, Gerard Wilkins, Randall Hendriks, P. Matsis, David W.M. Muller, Donald E. Cutlip	2010	30
16	EXCELLA™ First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions EuroIntervention ·Ribamar Costa, Alexandre Abizaid, Fausto Feres, Ricardo A. Costa, Ana C. Seixas, Felipe Maia, Luis Fernando Leite Tanajura, Rodolfo Staico, Dimytri Siqueira, Lynn Meredith, Vinayak Bhat, John Yan, John Ormiston, Amanda G.M.R. Sousa, Peter J. Fitzgerald, Eduardo Sousa	2008	27
17	Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial EuroIntervention ·William Wijns, Mathias Vrolix, Stefan Verheye, Danny Schoors, Ton Slagboom, M. Gosselink, Edouard Benit, Dennis Donohoe, Charlene Knape, Guilherme F. Attizzani, Alexandra J. Lansky, John Ormiston	2015	26
18	Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study EuroIntervention ·Ian Buysschaert, Christophe Dubois, Joseph Dens, John Ormiston, Stephen G. Worthley, Dougal McClean, Jan Paul Ottervanger, Ian T. Meredith, Neal Uren, William Wijns, R. Whitbourn, Roxana Mehran, Alexandra J. Lansky, Marzena Bichalska, Susanne Meis, Stefan Verheye	2013	24
19	Differences in Neointimal Thickness Between the Adluminal and the Abluminal Sides of Malapposed and Side-Branch Struts in a Polylactide Bioresorbable Scaffold JACC: Cardiovascular Interventions ·Juan Luis Gutiérrez‐Chico, Frank Gijsen, Evelyn Regar, Jolanda J. Wentzel, Bernard De Bruyne, Leif Thuesen, John Ormiston, Dougal R. McClean, Stephan Windecker, Bernard Chevalier, Dariusz Dudek, Robert Whitbourn, Salvatore Brugaletta, Yoshinobu Onuma, Patrick W. Serruys	2012	22
20	First human use of the TAXUs Petal paclitaxel-eluting bifurcation stent EuroIntervention ·John Ormiston, Thierry Lefèvre, Eberhard Grube, Dominic J. Allocco, Keith D. Dawkins	2010	22

About John Ormiston

John Ormiston is a scholar working on Cardiology and Cardiovascular Medicine, Surgery, Radiology, Nuclear Medicine and Imaging, Internal Medicine and Pulmonary and Respiratory Medicine, having authored 32 papers that have together received 1.6k indexed citations. Recurring topics across this work include Coronary Interventions and Diagnostics (24 papers), Cardiac Imaging and Diagnostics (12 papers), Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Cardiac Valve Diseases and Treatments (10 papers), Cerebrovascular and Carotid Artery Diseases (4 papers), Acute Myocardial Infarction Research (3 papers), Lipoproteins and Cardiovascular Health (3 papers) and Atrial Fibrillation Management and Outcomes (2 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (1.1k citations), Surgery (1.4k citations), Radiology, Nuclear Medicine and Imaging (424 citations), Pulmonary and Respiratory Medicine (462 citations) and Internal Medicine (49 citations). John Ormiston has collaborated with scholars based in New Zealand, Netherlands and Australia. Frequent co-authors include Dariusz Dudek, Mark Webster, Antonio Colombo, Leif Thuesen, Eduardo Sousa, Eulogio García, Wim van der Giessen, Silvio Klugmann, Marie‐Angèle Morel and Victor Legrand. Their work appears in journals such as EuroIntervention, Journal of the American College of Cardiology, JACC: Cardiovascular Interventions, American Heart Journal and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact